A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib

Archives of Dermatology

Volumn 148, Issue 12, 2012, Pages 1418-1420

  Giacchero, Damien ^a   Ramacciotti, Constanza ^c   Arnault, Jean Philippe ^a   Brassard, Maryse ^c   Baudin, Eric ^c   Maksimovic, Laurent ^a   Mateus, Christine ^a   Tomasic, Gorana ^a   Wechsler, Janine ^a   Schlumberger, Martin ^a,b   Robert, Caroline ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VANDETANIB;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEILITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DRY SKIN; DYSESTHESIA; ERYTHEMA MULTIFORME; FEMALE; FINGER MALFORMATION; FOLLICULITIS; GENITAL ERYTHEMA; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERTRICHOSIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OUTCOME ASSESSMENT; PARONYCHIA; PERIORBITAL EDEMA; PHOTOSENSITIVITY; PRIORITY JOURNAL; SKIN BIOPSY; SKIN LUPUS ERYTHEMATOSUS; SKIN TOXICITY; THYROID CANCER; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLICULITIS; HAND-FOOT SYNDROME; HUMANS; HYPERPIGMENTATION; MALE; MIDDLE AGED; PHOTOSENSITIVITY DISORDERS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; THYROID NEOPLASMS;

EID: 84871361940     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/2013.jamadermatol.192     Document Type: Article

References (9)

1. Robert C, Soria JC, Spatz A, et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005;6(7):491-500. (Pubitemid 40903630)
2. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res. 2003;9(4):1546-1556. (Pubitemid 36418413)
3. Wells SA Jr, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol. 2012;30(2):134-141.
4. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC). http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/ctc.htm#ctc-40-conversion. Accessed October 30, 2012.
5. Rosen AC, Wu S, Damse A, Sherman E, Lacouture ME. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(4):1125-1133.
6. Dummer R, Rinderknecht J, Goldinger SM. Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med. 2012;366(5):480-481.
7. Liu W, Baer MR, Bowman MJ, et al. The tyrosine kinase inhibitor imatinib mesylate enhances the efficacy of photodynamic therapy by inhibiting ABCG2. Clin Cancer Res . 2007;13(8):2463-2470. (Pubitemid 46698598)
8. Zheng LS, Wang F, Li YH, et al. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function. PLoS One. 2009;4(4):e5172.
9. Kong HH, Fine HA, Stern JB, Turner ML. Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol. 2009;145(8):923-925.